

# Long-term Stability of SGRQ Total Score in Individuals with AATD-associated Lung Disease Participating in AlphaNet's Disease Management Program Radmila Choate<sup>1</sup>, Kristen E. Holm<sup>2, 3</sup>, Robert A. Sandhaus<sup>2, 3</sup>, David M. Mannino<sup>4</sup>, Charlie Strange<sup>3,5</sup>

<sup>1</sup> University of Kentucky College of Public Health, Lexington, Kentucky; <sup>2</sup> Department of Medicine, National Jewish Health, Denver, Colorado; <sup>3</sup> AlphaNet, Inc., Coral Gables, Florida; <sup>4</sup> University of Kentucky College of Medicine, Lexington, Kentucky; <sup>5</sup> Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Medical University of South Carolina, Charleston, South Carolina

### Introduction

• St. George's Respiratory Questionnaire (SGRQ) is often used as an outcome measure to evaluate patient-perceived changes in health status. Research suggests that engagement in interventions such as pulmonary rehab or a new therapy is associated with stabilization or improvement in SGRQ scores over time.

The objectives of this study were to describe the longitudinal changes in HRQoL in people with AATD-associated lung disease participating in a disease management program and to evaluate factors associated with SGRQ trajectories.

### Methods

• This study included data collected via structured telephone interviews between 2008 and 2019 from 2,456 participants of AlphaNet, a not-for-profit health management organization for individuals with AATD in the United States who are prescribed augmentation therapy.

• Mixed effects models with random intercepts and slopes were used to assess longitudinal changes in SGRQ total and subscale scores in the overall cohort and by baseline variables of interest: age, sex, dyspnea severity, productive cough, oxygen use, and exacerbation frequency.



#### **Study Flow Diagram**

## Results

### **Baseline characteristics of the study population**, n=2,456

Age, years mMRC SGRQ total score SGRQ symptoms SGRQ activities SGRQ impact Number of SGRQ r Number of years of

#### Annual change in the mean SGRQ total score and subscales



#### Annual change in the mean SGRQ total and subscale scores by mMRC grade



Disclosures: This research was supported by an unrestricted grant from AlphaNet. RC reports research funding from Alpha-1 antitrypsin deficiency or COPD paid to the Medical University of South Carolina from Adverum, Arrowhead, AstraZeneca, CSA Medical, Grifols, Nuvaira, Takeda and Vertex. He is a medical director at AlphaNet. CS has consulted for Bronchus, Dicerna, GlaxoSmithKline, Pulmanage, and Vertex for Alpha-1 and/or COPD.

	Median (IQR)
	57 (50-64)
	2 (1-4)
	46 (31-60)
	46 (30-64)
	66 (48-86)
	32 (18-46)
neasurements	5 (3-8)
follow-up	6 (3-9)

- SGRQ total and impact scores – no significant change over time (p=0.96 and p=0.07)
- SGRQ activity and symptoms scores- significant change over time (p<0.001 and p<0.0001)
- Mean SGRQ total score change is well below the MCID of 4 points
  - SGRQ activity domain scores showed the highest annual worsening.
  - SGRQ symptoms domain demonstrated the greatest improvement over time.

# **Results (continued)**

#### SGRQ total score longitudinal trajectories by baseline mMRC grade



#### SGRQ total score longitudinal trajectories by baseline exacerbation frequency



### Conclusions

- Long-term stability in HRQoL measured by SGRQ was observed in this cohort of individuals with AATD-associated lung disease.
- These findings highlight the positive effect of participating in a disease management program on HRQoL in this population.



 SGRQ total score intercepts and slopes are significantly different by baseline mMRC grade (p<.0001)

SGRQ total score intercepts are significantly different by baseline exacerbation frequency (p<.0001) No difference in the slopes of

SGRQ total score by exacerbation frequency



